establish lab hold inc found
headquart alajuela costa rica
global innov market proprietari
devic suppli
billion
global augment reconstruct breast implant
commerci sale outsid unit state
sold countri top
market approv target late
reason report
initi coverag
initi formal research coverag establish lab
hold esta o/v invest rate
price target opinion esta motiva brand silicone-gel breast
implant potenti significantli disrupt exist
billion global market better clinic outcom enhanc
aesthet attribut result esta forecast grow excess
next prior realiz acceler
revenu growth follow expect commerci launch
 acknowledg need addit capit on-going
regulatori commerci risk esta clinic differenti
motiva portfolio possess suffici growth potenti enabl
share trade discount peer outperform
price target assum revenu multipl approxim
line compar med tech industri prevail peer
establish estim revenu earn estim
million per share million
consensu estim estim million
per share fall million consensu
rel discount valuat esta share current trade
revenu valu notabl discount compar
med tech industri peer trade averag like multipl
risk signific capit need estim esta
requir million anoth million capit prior
expect commerci regulatori
technolog risk assum typic follow-up esta
forecast achiev fda approv risk also exist
motiva favor self-report clinic result compar
favor rigor fda framework concentr
ownership insid control approxim compani
relat lock-up period expir mid discretionari
market breast augment subject chang dispos
incom societ view beauti entrench competitor agn
repres entrench diversifi global competitor
combin share addit field crowd
smaller region particip possess establish follow
respect region
import disclosur analyst certif page report access current disclosur
stephen inc cover compani client may refer
esta innov market proprietari devic suppli design
use estim billion global augment reconstruct
breast implant market market forecast exhibit compound-annual-growth-rate
complic rate competit offer addit provid enhanc
aesthet consum confid relat benefit
call esta provid investor opportun invest high-growth
global market player industry-disrupt technolog aesthet
stephen inc estim
esta ipo million share juli
esta report consensu revenu
esta announc transit direct sale forc uk
day cdrh gener plastic surgeri devic advisori
esta announc transit direct sale forc germani
day cdrh gener plastic surgeri devic advisori
esta report consensu revenu
revoc agn ce mark textur implant europ
esta report consensu revenu
account
total
corpor overview weight
con
con
con
favor demograph privat pay market
subject reimburs risk
today primarili target augment lt
plan expand reconstruct well
devic complic rate
forecast organ revenu compound-annual-growth-rate
chang
time
incumb focus matur offer
market ripe innov driven chang
come
growth forecast base share gain geograph
expans model
brand surgeri center support lt growth
estim esta requir million
anoth million capit prior
expect commerci
follow-up esta
forecast achiev fda approv
risk also exist motiva favor self-report
clinic result compar favor
rigor fda framework
concentr ownership
concentr ownership
concentr ownership
concentr ownership
insid control approxim compani
relat lock-up period expir mid
make million share free trade
breast augment subject
dispos incom societ view beauti
chang
global competitor combin share
addit field crowd smaller
possess establish
follow within respect region
corpor overview pontif futur
futur
futur
futur
market growth modestli acceler
risk concern assuag women
gravit natur ergonom implant
reconstruct procedur continu increas
esta sale compound-annual-growth-rate improv
convers direct sale select market
combin enhanc awar motiva
market growth remain forecast
gain assuag risk concern
increas reconstruct procedur off-set
econom concern bia toward natur
esta realiz increment share
compound-annual-growth-rate convers direct sale
select market combin enhanc awar
market growth declin
econom devic concern combin trend
esta forecast growth moder due capit
constraint challeng
compet
bundl offer larger particip result
revenu compound-annual-growth-rate
revenu estim increas
million million impli million
increas forecast annual revenu
assum target valuat multipl
current price target would increas
per esta share
revenu estim increas
million million
impli
million increas forecast annual revenu
assum target valuat multipl
current price target would increas
per esta share
revenu estim decreas
million million impli million
declin forecast annual revenu
assum discount target valuat
multipl current price target
would declin per esta
manag leadership personnel -- -- world class ensembl
manag leadership personnel
manag leadership personnel
manag leadership personnel
lab ceo
establish lab hold inc sinc
compani incept prior found
esta mr chacon-quir serv gener
manag aesthet medic devic
distribut busi latin america
busi develop manag plastic
reconstruct surgeri clinic costa rica
mr chacon quior earn baccalaur
academi de poiteier econom
attend univers massachusett
mr de mezervil appoint
serv variou role esta
recent compani vice presid
qualiti research develop
prior join esta mr de
mezervil held variou engin
qualiti manag posit allergan
degre busi administr
universidad interamericana de costa rica
bachelor degre industri
environment health safeti engin
instito tecnologico de costa rica
ms gaeta join esta juli
sinc serv compani cfo prior
join esta ms gaeta vice presid
corpor control inc
advisori director
transact restructur group
kpmg llp ms gaeta earn bachelor
scienc degre loyola marymount
mr dada appoint
serv manag oper
manufactur sinc prior join
allergan medic mr
dada earn undergradu licenti
degre industri engin
univers costa rica
establish lab support strong
leadership team addit notabl
personnel serv compani
scientif board medic board board
director particular note dr robert
langer global thought leader
mit institu professor issu pend patent cite
engin histori lead world largest biomed engin lab
director plastic surgeri research center univers manchest
industri expert biomechan engin
global kol aesthet reconstruct breast surgeri author atla
aesthet breast surgeri
global kol professor plastic surgeri univers sao paulo school
medicin
global kol director motviaedg
board director
founder ceo establish lab
ceo vivex biomed inc former presid life cell
view esta compel opportun aggressive-growth small cap med tech investor
compani potenti disrupt technolog portfolio breast implant relat technolog stand
drive signific share gain within estim billion global breast implant market
acknowledg signific need capit next three year entrench industri competit
remain optimist compani deliv compound annual organ revenu growth excess
prior acceler expect entri domest market
month price target assign peer averag revenu multipl essenti in-lin
consensu revenu estim
exist billion global privat pay market forecast exhibit compound-annual-growth-rate
rel lack product innov recent health concern make market ripe innov
establish lab potenti disrupt technolog portfolio usher new paradigm
clinic superior outcom drive global market share gain
above-averag organ growth premium privat pay market valu discount peer
stage global breast market
set
bil global expenditur
total expenditur breast augment
procedur total billion estim
market grow annual
intern societi plastic surgeon estim
global plastic surgeon
perform silicon breast
accord databas global femal
popul age total billion
forecast demograph grow
breast augment perform
equival global cosmet surgic
augment procedur perform
patient age patient
age year age
patient year age
femal popul continu grow see
continu adopt aesthet result signific
opportun esta gain market share drive
isap databas stephen inc estim
stage global breast market
set
jnj legaci franchis
domin domest silicon
breast implant market
share follow distant
posit share
also domin global
estim esta
combin global market despit
yet approv
addit releg
augment select market
stage size breast implant busi
set
global procedur
asap coher market insight datamintellig isap compani report stephen inc estim
stage size esta address market opportun
set
esta revenu geograph region
augment procedur countri
brazil account total revenu esta continu drive
share gain world largest market brazil account total breast
augment procedur esta revenu countri
account result brazil account half revenu
contribut latin america region total revenu europ repres
largest market total revenu term revenu esta aid higher
apac latin america region
isap compani report stephen inc estim
esta
stage larg domest opportun
stage larg domest opportun
set
 repres largest market opportun esta countri remain leader
breast augment procedur account total global procedur
esta receiv approv compani investig devic exempt clinic
trial led board-certifi plastic surgeon dr carolin glicksman first woman lead breast
implant clinic trial march enrol first patient april aesthet
cohort enrol reconstruct cohort continu enrol
specif singl arm multi-cent trial enrol patient age across
site sweden germani uk compani anticip complet
enrol oper period
isap compani report stephen inc estim
esta offer two version compani silicone-fil implant round implant
ergonomix implant round implant fill compani
design give round youth appear complet fill upper pole
breast ergonomix implant fill compani ultima
design natur look stand move lie importantli
implant featur esta smoothsilk/silksurfac technolog lead better outcom
tradit implant furthermor surfac featur compani blueseal technolog
design assur uniform barrier-lay prevent gel diffus
bodi
q-insid fda clear radio frequenc compon give patient
capabl verifi implant motiva implant surprisingli mani
patient awar manufactur implant produc
specif q-insid provid patient product famili volum
serial number lot number inform provid patient
piec mind know event devic safeti issu abl
see implant subject notic
truetissu
blueseal
blueseal technolog esta patent visual safeti barrier design give
surgeon confid implant shell importantli blueseal prevent
diffus silicon implant shell known gel bleed
furthermor compani truetissu technolog provid increas
strength flexibl due multilay system link compon
shell singl structur result insert easier surgeon
also provid enhanc safeti profil
esta current oper motviaimagin center one abl gather
inform breast augment subsequ procedur
perform compani divina simul technolog allow surgeon
captur patient bodi set data breast augment
consult portray simul patient look like variou
size implant importantli divina technolog abl use
portabl devic ipad
compani facebook page report
esta puregraft retractor offer
esta puregraft retractor offer
esta puregraft retractor offer
esta puregraft retractor offer
esta puregraft offer purifi fat tissu compani filtrat
technolog specif puregraft remov lipid blood within graft
import lipid blood within fat graft lead
inflamm tissu damag reduc graft retent esta bulb-cannula kit
compani single-us instrument design protect breast implant integr
fat graft procedur right esta retractor offer
improv eas use breast augment procedur though smaller
esta three brand surgeri benefit surgeon patient
surgeri util esta divina system motiva
implant puregraft autolog adipos tissu
motiva minimalscar use compani
motivaimagin ultralight led retractor
motiva insert sleev provid reduc
motivamint compani next gener
brand surgeri current develop
benefit patient allow surgeon
perform breast augment procedur
motivamint allow local anesthesia rather
gener anesthesia result faster
model assum esta clinic differenti motiva offer relat
tangibl consum benefit uniqu posit compani success gain
share within exist billion global breast aesthet marketplac
ruptur rate capsular contractur manufactur
ruptur rate capsular contractur
ruptur rate capsular contractur
ruptur rate capsular contractur
establish lab significantli lower report rate ruptur capsular
contractur versu competitor specif implant
compani sold esta implant incid rate less
ruptur capsular contractur
howev note esta data self-report shorter time period
versu data collect three competitor mandatori follow
note ruptur rate repres mri cohort respect studi consist patient
alcl manufactur
report case -- -- alcl
report case bia
report case bia
report case bia
clear esta motiva yet commerci avail howev highlight
domest bia-alcl data support assert primarili devic textur
rather implant categori issu support thesi market ripe
specif data present md anderson recent fda cdrh gener
plastic surgeri devic advisori committe meet fda maud databas
found aggress textur implant account report case
bia-alcl similarli md anderson track report found account
report case furthermor fda maud databas impli
biocel implant incid vs siltex similarli md anderson track
found biocel incid siltex
fda maud databas dr clemen md anderson
bii repres under-report complic associ breast implant
surgeri one possess far higher incid rate potenti affect
excess implant recipi bia-alcl
moreov bii offici acknowledg present specif ill
relat treatment often reimburs insur provid
women increasingli turn social media forum educ
discuss next step treatment perspect
opinion grow concern relat bia-alcl bii stand drive
increas adopt next gener technolog esta
demonstr superior clinic outcom rel incumb
recal fda first identifi possibl associ breast implant
develop bia-alcl sinc time per fda websit
review relat clinic literatur preponder data
definit suggest bia-alcl occur frequent follow implant
breast implant textur surfac rather smooth surfac
specif agn biocel implant aggress textur surfac
disproport higher number report bia-alcl case convers esta
smoothsilk offer one smoothest surfac date report
jone et plast reconstr surg atlan et journal mechan behavior
esta smoothsilk silksurfac
esta smoothsilk silksurfac
esta smoothsilk silksurfac
esta smoothsilk silksurfac
motiva implant highlight studi publish journal mechan behavior
biomed materi examin topographi surfac area implant look
surfac textur influenc capsul format tissu adher rat surfac imag result show
agn biocel implant exhibit anterior posterior surfac area mm
respect versu esta motiva silksurfac exhibit like textur mm respect
recal larger surfac area agn higher report case bia-alcl compar smooth
surfac studi also observ capsular format respons implant textur
period follow subcutan implant found tissu flat implant smallest
surfac area esta disorgan implant larger surfac area agn biocel
lastli studi also test tissu adher use peel test week follow implant
research found peak forc requir separ tissu increas complex surfac
textur specif peak forc esta silksurfac implant versu agn
al breast implant surfac textur impact host tissu respons journal mechan behavior biomed materi dec
esta histor valuat multipl compar compani analysi
stephen inc estim
stephen inc estim
breast implant revenu
estim esta realiz organ compound-annual-growth-rate
prior annual growth acceler
first full year contribut
annual revenu growth forecast stem
compound-annual-growth-rate zone revenu compound-annual-growth-rate zone
revenu growth
estim esta requir million
anoth million prior full scale unit state
commerci effort
combin favor geograph sale mix
enabl esta realiz gm expans
entri market provid
addit gm expans
addit estim esta clinic superior
motiva offer maintain flat blend price
assum esta achiev profit
forecast period due rise oper
expenditur notabl sale market
result forecast greater loss
consensu
esta histori breast augment
brief histori breast augment
first breast augment
procedur perform dr vincenz
czerni germani patient
tumor remov breast
wwii japanes women non-
medic grade silicon inject
breast howev often result
mark year modern breast
augment dr frank gerow dr
thoma cronin engin first silicon breast
implant timmi jean lindsey becam
first woman receiv silicon breast implant
manufactur sinc experi
variou shape textur implant
posit dubiou outcom
esta introduc motiva
implant silicon implant smooth
shell exhibit better clinic
outcom exist option
esta manufactur round
shape implant featur
blueseal technolog
esta implant q-insid technolog
dr gerow dr cronin
silk/surfac blueseal
compani report houston chronicl peter evolut breast implant plast surg
june receiv approv
june receiv approv
market natrel inspira
market natrel inspira
addit style natrel
addit style natrel
approv natrel inspira cohes
approv natrel inspira cohes
approv natrel inspira softtouch
approv natrel inspira softtouch
 dr hg invent
 dr hg invent
 arion laboratori
 laboratori
 cerepla found
 cerepla found
june introduc compani
june introduc compani
silicon fill breast implant
silicon fill breast implant
rang round anatom
rang round anatom
eurosilicon matrix
eurosilicon matrix
round collect south korea
round collect south korea
matrix brazil
matrix brazil
financ
financ
cereform breast implant round
cereform breast implant round
avail smooth surg
avail smooth surg
depend breast implant
depend breast implant
implant barrier layer
implant barrier layer
envelop inord prevent leakag
envelop order prevent leakag
autogen weld occlus
autogen weld occlus
disc envelop protect
disc envelop protect
ruptur
ruptur
hydrogel featur allow implant
hydrogel featur allow implant
transpar x-ray benefit
transpar x-ray benefit
envelop elast
envelop elast
strength compar silicon gel
strength compar silicon gel
implant furthermor ruptur
implant furthermor ruptur
occur breast slightli deflat
occur breast slightli deflat
prevent need mri
prevent need mri
featur filler complet
featur filler complet
biocompat biodegrad
biocompat biodegrad
impleo smooth nagotex mid-
impleo smooth nagotex mid-
textur surfac implant high
textur surfac implant high
cohes silicon gel size
cohes silicon gel size
cogel taper edg provid less
cogel taper edg provid less
visibl palpabl silogard
visibl palpabl silogard
barrier silogel form stabl high
barrier silogel form stabl high
configur variat
configur variat
come smooth cristallin micro-
come smooth cristallin micro-
textur surfac soft cohes
textur surfac soft cohes
less visibl palpabl
less visibl palpabl
compani report datamintellig
august partner tekno
surgic medic product distributor
ireland launch compani
novemb launch
clinic studi compani breast
compani nano-textur breast
short anatom tall anatom
 compani found
special manufactur
 chang joint ventur
cooper base
manag assess
guangdong food drug
practic inspect guangdong food
drug administr
 certif
august partner
sell belagel compani silicon
breast implant mexico
compani micro-textur breast
implant south korea
ideal implant launch
fund
manufactur compani
structur breast implant offer
decemb releas
studi show rel lower risk
augment reconstruct
collagen interfac
crystal lamb offer reduc risk
capsular contract due surfac
lamb cohes gel
cross-link compar standard
compani report datamintellig
aesthet merg
approv conduct clinic trial
april receiv approv
fda market mentor memorygel
extra silicon gel-fil breast implant
pma four new breast implant style
shape round addit
new profil size option nine
approv compani opu ultra
high-profil silicon gel implant use
breast reconstruct procedur
avail gel high
moder plu moder low
hsc silicon gel
compani report datamintellig
review warranti program manufactur
review warranti program manufactur
review warranti program manufactur
review warranti program manufactur
alway cofid warranti motiva
year
year
implant ruptur
year capsular
contractur late form seroma
motiva
program
motiva program ruptur capsular
diagnost test
toward remov
assocait scar tissu
fda first identifi possibl link breast implant develop refer breast implant
associ anaplast larg cell lymphoma bia-alcl possess suffici clinic evid definit
determin factor increas associ patient risk
subsequ world organ design breast implant-associ anaplast larg cell lymphoma
bia-alcl t-cell lymphoma develop follow breast implant swerdlow et al sinc note bia-
alcl typic origin capsul around breast implant present fluid collect tumor adjac implant
decemb allergan plc deni renew compani ce mark distribut textur implant
march biocel textur implant recal european countri well israel brazil result
french nation agenc medicin health product safeti conven intern expert regul
public confer februari discuss safeti textur breast implant releas conclus public
monday march tuesday march unit state food drug administr fda conven public advisori
meet gener plastic surgeri devic panel chair frank lewi jr execut director emeritu american
board surgeri addit vote panel member includ ann marilyn leitch professor depart surgeri
univers texa southwestern karen burk ph new york-bas practic dermatologist
importantli panel task evalu make recommend revoc temporari suspens
previous fda-approv silicon breast implant current commerci avail unit state panel
task make recommend suspend limit use textur silicon breast implant
specif public advisori meet gener plastic surgeri devic panel task six item
discuss best modifi util registri data character longitudin outcom better inform patient
make recommend relat next step character bia-alcl incid relat risk factor
discuss method assess address breast implant ill symptom
discuss evidentiari requir assess safeti effect benefit/risk use surgic
mesh breast reconstruct mastopexi procedur
discuss mri screen recommend silent silicon gel fill breast implant ruptur
discuss role respons stakehold commun implant relat risk benefit patient
isap compani report stephen inc estim
fda cdrh gener plastic surgeri devic advisori committe meet result recommend fda
implement temporari moratorium much less perman ban silicon gel breast implant specif textur
silicon gel implant due bia-alcl concern
consensu exist among panel member definit causal relationship exist breast implant breast
consist transpar comprehens inform consent process involv surgeon patient assur
mandat fda
surpris panel perceiv hesit entertain temporari ban allergan plc textur implant due
inconclus incomplet data unit state
data two import data point first day panel proceed depict incid rate bia-
alcl bii manufactur data show implant associ disproportion higher incid rate
bia-alcl bii compani estim domest market share opu implant possess
favor clinic outcom rel compet offer
specif implant account fda maud databas citat bia-alcl
md track data bia-alcl versu account fda maud
databas citat md anderson data
md anderson data conclud biocel textur silicon implant like develop bia-alcl
siltex textur silicon gel implant despit possess estim greater share domest
market similarli regard incid breast implant ill bii implant statist signific
greater incid rate associ symptom either
bii incid data like skew favor due compani util core studi data
report purpos studi may suffici power identifi report
first day panel hear data present re-affirmed view manufactur favor clinic
outcom like establish lab realiz market share gain mandatori comprehens
inform consent process women expect increasingli opt devic favor rel risk
advisori committe astut discern textur surfac creat equal note base data
present global to-dat relat textur implant well data md clear textur
surfac rate complic
addit sever member advisori committe express desir know differ bia-alcl incid rate
textur silicon gel implant lowest incid rate bia-alcl smooth silicon gel implant data
current exist
follow day view base discuss attend surgeon industri particip patient advoc
advisori committe meet industri growth like revert histor rate later year
compani report stephen inc estim
follow day becam clear bii repres under-report complic associ breast implant surgeri
one possess far higher incid rate potenti affect excess implant recipi bia-alcl
bii offici acknowledg present specif ill relat treatment often
reimburs insur provid women increasingli turn social media forum educ
discuss next step treatment perspect result concern social media interact
sincer definit valu still may fulli depict best clinic practic result women elect
either select implant forgo appropri treatment relat ill
repres far greater risk industri growth rate incid bia-alcl
advisori committe member gener abstain specif cite disproportion high incid rate bia-
alcl well bii associ allergan textur silicon gel implant
howev conclus day one advisori committe member indic surpris agenc
assign specif scrutini allergan textur silicon gel implant base data avail unit
state prior regulatori action taken eu israel brazil
advisori committe recommend fda mandat comprehens standard inform consent process
patient inform patient requir addit surgeri implant lifetim devic
repres lifetim commit yet definit known data suggest predispos
factor exist may place prospect patient greater risk develop bia-alcl bii breast implant relat
complic inform consent process determin share decis make process surgeon
patient relat parti spous child signific research bulletin march stephen inc page
addit advisori panel recommend fda also consid make physician outsid plastic surgeri
awar breast implant complic place black warn select breast implant provid patient
ingredi list relat prospect implant work surgic societi influenc surgeon better educ
patient provid balanc scientif public servic announc women media increas awar
better educ patient
may fda issu formal statement relat regul breast implant
specif fda state agenc improv avail inform risk biaalcl textur
implant system symptom work facilit access aforement provid consum
requir individu medic devic report file made publicli avail maud elimin summari
report partner registri increas real world safeti perform data ban
temporarili suspend textur silicon gel implant base current avail inform
compani report stephen inc estim
breast uneven appear far size shape breast level
pain breast area includ nippl
thin shrink skin breast area
subcutan hard lump around implant mistaken cancer mammographi result addit
tighten tissu capsul around implant result breast becom firm hard sever
squeez implant
chest wall rib cage appear deform
leakag saltwat solut saline-fil implant often due valv leak ruptur partial complet
collaps implant
incis site take longer normal heal never heal properli
situat implant appear skin result skin break
collect blood near surgic site may caus swell bruis pain hematoma typic occur
soon surgeri addit time injuri breast bodi toler small hematoma
larg one may requir addit medic intervent surgic drain
injuri damag tissu breast implant due breast implant surgeri
infect occur wound contamin microorgan bacteria fungi surgeri relat
infect appear within day week howev infect possibl time surgeri implant remov
may need infect respond antibiot
respons bodi infect injuri demonstr pain red swell warmth loss function
lymphedema
swollen enlarg lymph node
implant correct posit breast occur surgeri shift caus
graviti trauma capsular contractur
dead skin tissu around breast necrosi caus sever factor includ infect smoke use
steroid surgic breast pocket chemotherapy/radi excess heat cold therapi
chang feel nippl and/or breast sensat vari degre may temporari perman may affect sexual respons breast feed
breast implant felt skin
breast sag usual result age pregnanc weight loss
bleed time surgeri caus chang skin color expect symptom due surgeri like
tear hole breast implant outer shell
collect fluid around implant may caus swell pain bruis bodi may absorb small
seroma larg one requir surgic drain
rash around breast area
patient doctor satisfi overal appear implant base style size use
implant visibl skin
wrinkl implant felt visibl skin
histor project incom statement
histor project incom statement
histor project incom statement
histor project incom statement
compani report stephen inc estim
histor project balanc sheet
histor project balanc sheet
histor project balanc sheet
histor project balanc sheet
compani report stephen inc estim
histor project statement flow
histor project statement flow
histor project statement flow
histor project statement flow
compani report stephen inc estim
histor project ratio
histor project ratio
histor project ratio
histor project ratio
compani report stephen inc estim
compani report stephen inc estim
analyst primarili respons prepar content report certifi view express report
accur reflect analyst person view subject compani secur ii part analyst compens
directli indirectli relat specif recommend view express analyst report
